Melane Sampson, Author at BioTuesdays

Developments

Cognition lengthens Zervimesine program in DLB

Cognition Therapeutics (NASDAQ: CGTX) has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB) from the original 12 months to include several more months of treatment. According...

February 6, 2026

Developments

PRO FAMILIA and Profound mark 500 Sonalleve Procedures; expand access to incision-free women’s healthcare

Profound Medical (NASDAQ:PROF; TSX:PRN) announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve Procedure. The MRI-guided therapy provides women with a non-surgical...

February 5, 2026

Developments

JPO grants patent to Marvel for MB-204

Marvel Biosciences (TSXV: MRVL; OTCQB: MBCOF) has been granted a patent for its lead therapeutic candidate MB-204 by the Japanese Patent Office (JPO) covering composition of matter and methods of use claims. MB-204 is a...

February 4, 2026

Developments

FDA grants Fast Track Designation to Cumberland’s ifetroban DMD program

Cumberland Pharmaceuticals (NASDAQ: CPIX) has received Fast Track Designation from the FDA for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients. The FDA has...

February 4, 2026

Executive Moves

LeonaBio appoints industry veteran Mark F. Kubic as CBO

LeonaBio (NASDAQ: LONA) has appointed Mark F. Kubic as chief business officer (CBO) to lead the company’s business development strategy and execution. Mr. Kubik served as a strategic consultant to LeonaBio and played a...

February 3, 2026

Developments

FDA clears Nanox’s TAP2D image enhancement technology

Nanox (NASDAQ: NNOX) has announced receiving FDA 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. According to Nanox, the FDA...

February 3, 2026

Feature

Astrocyte delivering first-in-class approach to brain injury neuroprotection

Closely held Astrocyte Pharmaceuticals is developing a new category of neuroprotective therapies aimed at reducing early brain damage following stroke, concussion, and traumatic brain injury (TBI). By harnessing the...

February 3, 2026

Executive Moves

STAAR appoints Warren Foust and Deborah Andrews as interim co-CEOs

STAAR Surgical (NASDAQ: STAA) has announced that its board of directors has appointed Warren Foust, president and CEO, and Deborah Andrews, CFO, as interim co-CEOs, effective yesterday. According to STAAR, the board’s...

February 2, 2026

Developments

USPTO grants Acurx Pharmaceuticals patent for DNA Polymerase IIIC inhibitors

Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the U.S. Patent and Trademark Office (USPTO) covering DNA Polymerase IIIC inhibitors including compositions of matter, methods of use, and...

February 2, 2026

Developments

Publication supports scientific rationale for Palvella’s QTORIN in DSAP

Palvella Therapeutics (NASDAQ: PVLA) announced that Clinical and Experimental Dermatology has published a peer-reviewed systematic review synthesizing clinical evidence on off-label topical statin use in porokeratosis...

February 2, 2026

Author - Melane Sampson

Cognition lengthens Zervimesine program in DLB

PRO FAMILIA and Profound mark 500 Sonalleve Procedures; expand access to incision-free women’s healthcare

JPO grants patent to Marvel for MB-204

FDA grants Fast Track Designation to Cumberland’s ifetroban DMD program

LeonaBio appoints industry veteran Mark F. Kubic as CBO

FDA clears Nanox’s TAP2D image enhancement technology

Astrocyte delivering first-in-class approach to brain injury neuroprotection

STAAR appoints Warren Foust and Deborah Andrews as interim co-CEOs

USPTO grants Acurx Pharmaceuticals patent for DNA Polymerase IIIC inhibitors

Publication supports scientific rationale for Palvella’s QTORIN in DSAP

Subscribe